By Bill Sardi

Author of the newly published book "You Don't Have To Be Afraid Of Cancer Anymore
http://www.thecancerbook.com.


News headlines encircle the globe --- researchers will launch a so-called new and promising type of cancer-cell killing immune trial next summer. The news story originates from a discovery, announced in 2003, that Wake Forest University researchers discovered a laboratory mouse that was totally cancer resistant. A follow-up study showed that white-blood cells from "cancer-proof" mice could be infused into mice with cancer and produce complete eradication of their tumors. Now a human trial looms to see if it will produce the same result.

But there is much more to this story -- many questions remain unanswered (and un-asked), and there is puzzlement over misdirected science.

Beginning in 2003 when Wake Forest researchers announced the discovery of a cancer-proof mouse, there was something odd about their report. The tumor-resistant mouse was discovered in 1999, but the discovery wasn't reported till 4 years later. Why the delay in airing such a remarkable discovery?

Then later, researchers reported they had bred around 800 mice that carry the same cancer-cell killing immunity as their ancestor, meaning this trait is genetically transferred to offspring, probably by a single gene.

Since humans and mice share 98% of the same genes, there was hope that a parallel gene could be found in humans that would confer immunity against cancer. But no gene array studies have commenced, or if they have, they are being kept in a laboratory closet. At the time, researchers said there would be vigilant pursuit to find the gene. But so far, nothing.

The bigger story

Then researchers conducted an informal study of 100 human volunteers. They made a startling discovery that, so far, has been downplayed.

Some people exhibit weak immunity against cancer, while the vast majority have average immunity. But a very small number of people exhibit the same vigorous ability to kill cancer cells as the cancer-proof mice in the laboratory. White blood cells taken from some participants killed close to 97 per cent of the cancer cells in 24 hours, while samples from others killed only two per cent.

Cancer-proof humans exist!! Why this discovery isn't making headline news across the globe goes unexplained. The major news story, and scientific discovery, is being buried.

Controlling factors

Furthermore, researchers also found that this unusual immunity is diminished by advancing age, abolished by stress and is controlled by the seasons --- cancer-cell killing peaks in summer months and wanes in winter.

This means immunity against cancer is modifiable. Investigators point to the strong possibility that vitamin D, the sunshine vitamin, may heighten human immunity. Researchers plan to infuse cancer-killing cells from donors into cancer patients, but the experiment has to wait till next summer because nobody seems to have any cancer-killing during the winter months. This is when vitamin D levels are lowest.

Led astray

A recent study corroborates the vitamin D theory of cancer. Women in Nebraska who took 1100 International Units of supplemental vitamin D3 for 4 years experienced a 60-77% decline in cancer risk. Furthermore, it has been known for decades that cancer rates are lowest near the Equator where solar UV radiation is most intense.

An hour of total-body sun exposure at noontime in the summer in Arizona will produce up to 10,000 units of vitamin D. The liver stores vitamin D for future use.

But the research is directed away from vitamin D towards risky treatment, not finding the gene that would confer to humans complete immunity from cancer, nor further exploration into how vitamin D therapy might work to treat or prevent cancer.

Infusion therapy

What cancer researchers want to do is infuse granulocytes from healthy donors into cancer patients. Granulocytes are a type of white blood cell filled with microscopic granules that secrete enzymes that literally digest invading tumor or germs cells.


Granulocytes are already taken from donors and given to some patients whose immune systems have been depleted by chemotherapy, but they are yet to be used to treat cancer directly.

But this type of therapeutic infusion of granulocytes is not new. It is performed after cancer chemotherapy to reduce the number of infections following treatment.
In one recently published study, leukemia patients received infusions of granulocyte colony-stimulating factor, a hormone that stimulates production of granulocytes like neutrophils. Of 20 leukemia patients treated, 8 patients survived in complete remission for a period of 3 years. These were end-stage leukemia cases that had failed stem-cell therapy. [Haematologica 92 (3):414-7, March 2007]

Life threatening

However, granulocyte infusion can also induce a life-threatening host-graft reaction.
In a recent study conducted in France, researchers found life-threatening host-graft reactions emanating from infusion of progenitor cells (similar to stem cells) are provoked by the number of granulocytes in the infusion. [Transfusion 47 (7): 1268-75, 2007]
Wake Forest University researchers say they will attempt to minimize the possibility of these reactions. However, one wonders if this study is being designed to fail. Will the treatment be worse than the disease?

Innate immunity

Wake Forest University researchers previously identified white blood cells that comprise the innate immune system as the chief cancer cell killers. These are neutrophils, natural killer cells and macrophages. They identify, seek out and destroy cancer cells by creating a burst of free radicals inside the tumor cell. Neutrophils are particularly powerful because they not only circulate in the blood like macrophages and natural killer cells, but they move into tissues, like solid tumors. Neutrophils also play a role in activating the adaptive immune system, which are comprised of T cells and B cells.
.


Granulocytes

There is much the public is not being told here. There are ways to switch genes on molecularly. Nutrients can do this as well as drugs. Where is the gene in humans that exerts complete protection from cancer and which molecules activate this gene? Apparently, one of them is vitamin D.

There are also ways, using dietary supplements, to 'weaponize' vitamin D so its cancer-cell killing capacity is many times greater. Wake Forest University researchers say they found some people have 100 times greater immunity against cancer than others.

A special 30-page report entitled "Cancer-Proof Humans" has been written and will now accompany all orders for the book "You Don't Have To Be Afraid Of Cancer Anymore." The report reveals what cancer researchers are hiding --- that there are ways to produce "super immunity" from cancer (and infections). To find out more, visit
http://www.thecancerbook.com


Copyright 2007 Bill Sardi, Knowledge of Health, Inc.



The news report: Cancer cure 'may be available in two years'

By Nic Fleming Science Correspondent
Last Updated: 2:08am BST 20/09/2007

Cancer sufferers could be cured with injections of immune cells from other people within two years, scientists say.
US researchers have been given the go-ahead to give patients transfusions of "super strength" cancer-killing cells from donors.
Dr Zheng Cui, of the Wake Forest University School of Medicine, has shown in laboratory experiments that immune cells from some people can be almost 50 times more effective in fighting cancer than in others.
Dr Cui, whose work is highlighted in this week's New Scientist magazine, has previously shown cells from mice found to be immune to cancer can be used to cure ordinary mice with tumours.
The work raises the prospect of using cancer-killing immune system cells called granulocytes from donors to significantly boost a cancer patient's ability to fight their disease, and potentially cure them.
The US Food and Drug Administration (FDA) last week gave Dr Cui permission to inject super-strength granulocytes into 22 patients.
Dr Cui said: "Our hope is that this could be a cure. Our pre-clinical tests have been exceptionally successful.
"If this is half as effective in humans as it is in mice it could be that half of patients could be cured or at least given one to two years extra of high quality life.
"The technology needed to do this already exists, so if it works in humans we could save a lot of lives, and we could be doing so within two years."
Dr Cui is confident patients could benefit from the technique quickly because the technology used to extract granulocytes is the same as that already used by hospitals to obtain other blood components such as plasma or platelets.
Prof Gribben, a cancer immunologist at Cancer Research UK's experimental centre at St Bartholomew's Hospital, London, said: "The concept of using immune system cells to kill off someone else's cancer is very, very exciting."
Dr Cui, who presented his latest findings at an anti-ageing conference in Cambridge last week, extracted granulocytes from 100 people, including some with cancer.
When the immune cells were mixed with cervical cancer cells, those from different individuals demonstrated vastly varying abilities to fight the cancer.
Those of the strongest participants killed close to 97 per cent of the cancer cells in 24 hours, while those of the weakest killed only two per cent.
The abilities of the cells of participants aged over 50 were lower than average, and those of cancer patients even lower.
Dr Cui noticed that the strength of a person's immune system to combat cancer can also vary according to how stressed they are and the time of year.
Initial experiments suggest it may be possible to transfer granulocytes which have demonstrated strong cancer-fighting powers into cancer sufferers.
In 1999 Prof Cui and colleagues discovered a male mouse that appeared to be completely resistant to virulent cancer cells of several different types.
Since then more than 2000 mice in 15 generations have been bred from the original cancer-free mouse and 40 per cent of the offspring have inherited the immunity.
With the immune system, some types of cells which provide "innate immunity" are constantly on patrol for foreign invaders, while others have to firstly learn to identify a specific threat before going on the attack.
Scientists developing cancer vaccines have generally attempted to stimulate responses in the immune system cells that require prior exposure.
Last year Dr Cui caused shockwaves in the cancer research community when he identified granulocytes as the cells responsible for the mouse cancer immunity - because they are among those which act automatically.
Prof Gribben said: "This is surprising because it goes against how we thought immune system works against cancer. It makes us think again about our preconceived notions."
Prof Cui injected granulocytes from immune mice into ordinary mice, and found it was possible to give them protection from cancer.
Even more excitingly he found the transfusions caused existing cancers to go into remission and to clear them completely within weeks.
A single dose of the cells appeared to give many of the mice resistance to cancer for the rest of their lives.
Granulocyte transfusion has previously been used to try to prevent infections in cancer patients whose immune systems have been weakened by chemotherapy.
However their effectiveness has been unclear because they have mainly been given to patients in an advanced stage of disease.
Prof Gribben warned the US researchers would have to be careful to avoid other immune system cells from the donor proliferating in the patient's body.
He added: "If they're using live cells there is a theoretical risk of graft-versus-host disease, which can prove fatal."
Dr Cui said he is working on ways to minimize this risk.


http://www.knowledgeofhealth.com